ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models
James Spargo | July 15, 2024 | News story | Research and Development | Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug
Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies for STP125G, an siRNA therapeutics targeting Apolipoprotein C3 (ApoC3). These studies strongly support the Investigational New Drug (IND) filing with the US Food and Drug Administration (FDA).
STP237G is a late-stage preclinical candidate that is the first dual-targeted medication based on GalAhead muRNA technology. When undertaking an efficacy evaluation with a non-human primate model, the maximum target silencing efficacy was achieved at 10 mg/kg dosage around week four, and was maintained for an additional nine weeks.
A single subcutaneous administration of 50mg/kg, 100mg/kg or 250mg/kg produced a satisfactory safety readout. For all three high dosages, the maximal target silencing efficacies were comparable to a level of 10mg/kg.
Dr Patrick Lu, founder, chairman of the Board, executive director, president and CEO of Sirnaomics commented: “STP125G is the second drug candidate based on our GalAhead mxRNA technology that has shown excellent safety and potent efficacy results with the NHP models. Its long-lasting silencing activity against ApoC3 may provide better therapeutic benefit to patients suffering cardiovascular conditions than those of antisense and other siRNA drugs. The data readouts further validated STP125G as a novel siRNA therapeutic candidate for treatment of hypertriglyceridemia and other cardiovascular diseases, using our proprietary GalAhead-based delivery technology.”
Chiani-Rae Garland
Related Content
Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance
Spero Therapeutics has announced that it has gained US Food and Drug Administration (FDA) clearance …
AstraZeneca’s Forxiga approved in China for chronic heart failure treatment
AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk …
Novo Nordisk’s Wegovy reduces risk of cardiovascular events
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a …
